With the US approval of its combination therapy for glaucoma Rocklatan, Aerie Pharmaceuticals Inc. now has two glaucoma eye-drop products on the market and the firm is agnostic as to which product doctors or patients choose in the early going.
Aerie Looks To Grow Its Two Glaucoma Products In Tandem
The approval of combo therapy Rocklatan gives Aerie two approved glaucoma products; Rhopressa quickly attained wide market access in the US and Aerie expects Rocklatan to fare the same.
More from New Products
• By
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
More from Scrip
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.